<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">TBMHbp4BdB67pd8NXvPWkSH</article-id>
      <article-id pub-id-type="other">00007</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000600007</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200607</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000600007</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efeito da perda ponderal induzida pela cirurgia bari&#225;trica sobre a preval&#234;ncia de s&#237;ndrome metab&#243;lica</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Monteiro J&#250;nior</surname>
            <given-names>Francisco das Chagas</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva J&#250;nior</surname>
            <given-names>Wellington Santana da</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Salgado Filho</surname>
            <given-names>Natalino</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ferreira</surname>
            <given-names>Pedro Ant&#244;nio Muniz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ara&#250;jo</surname>
            <given-names>Gutenberg Fernandes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mandarino</surname>
            <given-names>Nat&#225;lia Ribeiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbosa</surname>
            <given-names>Jos&#233; Bonif&#225;cio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lages</surname>
            <given-names>Joyce Santos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lima</surname>
            <given-names>Jos&#233; de Ribamar Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Monteiro</surname>
            <given-names>Carolina Cipriano</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Lu&#237;s</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Universidade Federal do Maranh&#227;o</institution>
        <institution content-type="orgdiv1">Hospital Universit&#225;rio </institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>06</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>6</issue>
      <fpage>452</fpage>
      <lpage>456</lpage>
      <history>
        <date date-type="accepted">
          <day>09</day>
          <month>07</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>19</day>
          <month>06</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>17</day>
          <month>05</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A s&#237;ndrome metab&#243;lica (SM) est&#225; frequentemente ligada ao excesso de peso e melhora com a perda ponderal, sendo esperado que essa melhora seja proporcional &#224; intensidade dessa perda. OBJETIVO: Avaliar o impacto da perda ponderal induzida pela cirurgia bari&#225;trica (CB) sobre a preval&#234;ncia da SM, em m&#233;dio prazo. M&#201;TODOS: Foram analisados 35 pacientes submetidos &#224; cirurgia de by-pass gastrojejunal em Y de Roux, no per&#237;odo de outubro de 2001 a outubro de 2005, em nosso HU, sendo 88,5% do sexo feminino, com uma m&#233;dia de idade de 37,8&#177;11,1 anos e um IMC m&#233;dio de 45,0&#177;6,2 kg/m&#178;. Na primeira etapa da pesquisa, foram obtidos dados demogr&#225;ficos e cl&#237;nico-antropom&#233;tricos antes da realiza&#231;&#227;o da CB, incluindo os crit&#233;rios para o diagn&#243;stico da SM, de acordo com as diretrizes do NCEP dos Estados Unidos. Na segunda etapa, os pacientes operados foram reavaliados ambulatorialmente quanto &#224; preval&#234;ncia da SM. RESULTADOS:Antes da cirurgia, a SM foi diagnosticada em 27 pacientes (77,1%). Em reavalia&#231;&#227;o 34,4&#177;15 meses ap&#243;s a cirurgia, observou-se uma queda do IMC m&#233;dio para 28,3&#177;5,0 kg/m&#178; e a SM foi detectada em apenas dois pacientes (5,7%) (p&lt;0,001). A preval&#234;ncia dos crit&#233;rios cintura abdominal, glicemia, press&#227;o arterial, HDL-colesterol e triglicer&#237;deos foi reduzida em, respectivamente, 45,8%, 83%, 87,5%, 57,13% e 94%. CONCLUS&#195;O: A SM &#233; ocorr&#234;ncia comum em obesos candidatos &#224; CB e esse procedimento se mostrou extremamente eficaz na indu&#231;&#227;o da regress&#227;o da s&#237;ndrome, verificando-se redu&#231;&#227;o expressiva da preval&#234;ncia de todos os crit&#233;rios do NCEP.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>S&#237;ndrome metab&#243;lica</kwd>
        <kwd>preval&#234;ncia</kwd>
        <kwd>obesidade</kwd>
        <kwd>cirurgia bari&#225;trica</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>17</day>
        <month>07</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> DISLIPIDEMIAS</p>
    <p>Efeito da perda ponderal induzida pela cirurgia bari&#225;trica sobre a preval&#234;ncia de s&#237;ndrome metab&#243;lica</p>
    <p>
      <bold>Francisco das Chagas Monteiro J&#250;nior; Wellington Santana da Silva J&#250;nior; Natalino Salgado Filho; Pedro Ant&#244;nio Muniz Ferreira; Gutenberg Fernandes Ara&#250;jo; Nat&#225;lia Ribeiro Mandarino; Jos&#233; Bonif&#225;cio Barbosa; Joyce Santos Lages; Jos&#233; de Ribamar Oliveira Lima; Carolina Cipriano Monteiro</bold>
    </p>
    <p>Hospital Universit&#225;rio da Universidade Federal do Maranh&#227;o, S&#227;o Lu&#237;s, MA - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="end">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold>A s&#237;ndrome metab&#243;lica (SM) est&#225; frequentemente ligada ao excesso de peso e melhora com a perda ponderal, sendo esperado que essa melhora seja proporcional &#224; intensidade dessa perda. </p>
    <p><bold>OBJETIVO: </bold>Avaliar o impacto da perda ponderal induzida pela cirurgia bari&#225;trica (CB) sobre a preval&#234;ncia da SM, em m&#233;dio prazo. </p>
    <p><bold>M&#201;TODOS: </bold>Foram analisados 35 pacientes submetidos &#224; cirurgia de <italic>by-pass</italic> gastrojejunal em Y de Roux, no per&#237;odo de outubro de 2001 a outubro de 2005, em nosso HU, sendo 88,5% do sexo feminino, com uma m&#233;dia de idade de 37,8&#177;11,1 anos e um IMC m&#233;dio de 45,0&#177;6,2 kg/m<sup>2</sup>. Na primeira etapa da pesquisa, foram obtidos dados demogr&#225;ficos e cl&#237;nico-antropom&#233;tricos antes da realiza&#231;&#227;o da CB, incluindo os crit&#233;rios para o diagn&#243;stico da SM, de acordo com as diretrizes do NCEP dos Estados Unidos. Na segunda etapa, os pacientes operados foram reavaliados ambulatorialmente quanto &#224; preval&#234;ncia da SM. </p>
    <p><bold>RESULTADOS:</bold>Antes da cirurgia, a SM foi diagnosticada em 27 pacientes (77,1%). Em reavalia&#231;&#227;o 34,4&#177;15 meses ap&#243;s a cirurgia, observou-se uma queda do IMC m&#233;dio para 28,3&#177;5,0 kg/m<sup>2</sup> e a SM foi detectada em apenas dois pacientes (5,7%) (p&lt;0,001). A preval&#234;ncia dos crit&#233;rios cintura abdominal, glicemia, press&#227;o arterial, HDL-colesterol e triglicer&#237;deos foi reduzida em, respectivamente, 45,8%, 83%, 87,5%, 57,13% e 94%. </p>
    <p><bold>CONCLUS&#195;O:</bold> A SM &#233; ocorr&#234;ncia comum em obesos candidatos &#224; CB e esse procedimento se mostrou extremamente eficaz na indu&#231;&#227;o da regress&#227;o da s&#237;ndrome, verificando-se redu&#231;&#227;o expressiva da preval&#234;ncia de todos os crit&#233;rios do NCEP.</p>
    <p><bold>Palavras-chave: </bold>S&#237;ndrome metab&#243;lica, preval&#234;ncia, obesidade, cirurgia bari&#225;trica.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>O termo s&#237;ndrome metab&#243;lica (SM) descreve uma condi&#231;&#227;o de ocorr&#234;ncia predominante em pa&#237;ses civilizados cujas manifesta&#231;&#245;es mais proeminentes s&#227;o a obesidade andr&#243;ide (abdominal), o diabete melito tipo 2, a hipertens&#227;o arterial e desordens do metabolismo dos lip&#237;dios, que se traduzem especialmente pela presen&#231;a de part&#237;culas de LDL-colesterol pequenas e densas, HDL-colesterol baixo e eleva&#231;&#227;o da taxa de triglic&#233;rides no sangue. Estima-se que a SM afete cerca de 20% a 30% da popula&#231;&#227;o em idade m&#233;dia e avan&#231;ada<sup>1,2</sup>. Sua maior import&#226;ncia reside no fato de que tem sido implicada com um aumento significativo do risco de morbidade e mortalidade cardiovascular<sup>3</sup>.</p>
    <p>Acredita-se que a obesidade, em especial a adiposidade abdominal, seja de fundamental import&#226;ncia no desenvolvimento da s&#237;ndrome, mediante a indu&#231;&#227;o da resist&#234;ncia &#224; insulina, dist&#250;rbio apontado como desencadeador das outras altera&#231;&#245;es descritas<sup>1</sup>. Estudos epidemiol&#243;gicos t&#234;m demonstrado que o excesso de peso responde por 78% dos casos de hipertens&#227;o em homens e 65% dos casos em mulheres<sup>4</sup>, bem como eleva o risco de ocorr&#234;ncia de diabete melito tipo 2 em 10 vezes<sup>5</sup>. Um &#237;ndice de massa corporal &gt; 35 kg/m<sup>2</sup> aumenta o risco de desenvolver diabete melito em 93 vezes em homens e 42 vezes em mulheres<sup>5</sup>. Esses dados s&#227;o bastante alarmantes, uma vez que a preval&#234;ncia de obesidade tem aumentado de forma descontrolada nos pa&#237;ses industrializados<sup>6</sup>. </p>
    <p>Os benef&#237;cios da redu&#231;&#227;o ponderal obtida a partir de mudan&#231;as no estilo de vida, como ado&#231;&#227;o de dieta hipocal&#243;rica e pr&#225;tica de atividade f&#237;sica, apresentam-se largamente documentados<sup>7</sup>. Em portadores de obesidade m&#243;rbida, refrat&#225;ria &#224;s medidas conservadoras, a cirurgia de redu&#231;&#227;o do est&#244;mago (cirurgia bari&#225;trica) tem proporcionado nos &#250;ltimos anos perdas ponderais importantes nesses indiv&#237;duos, com consequente melhora das co-morbidades e da qualidade de vida<sup>8</sup>. </p>
    <p> O estudo <italic>Swedish Obese Subjects</italic> (SOS), publicado recentemente, que acompanhou 4.047 obesos durante 10 anos, sendo 2.010 submetidos &#224; cirurgia bari&#225;trica e 2.037 mantidos sob tratamento convencional (grupo controle), demonstrou uma taxa de mortalidade por todas as causas menor no grupo cir&#250;rgico. Embora n&#227;o-randomizado, este ensaio trouxe importante evid&#234;ncia adicional acerca da seguran&#231;a e benef&#237;cio da cirurgia bari&#225;trica<sup>9</sup>.</p>
    <p>Especificamente em rela&#231;&#227;o &#224; SM, pequenos estudos iniciais, com acompanhamento de at&#233; um ano ap&#243;s a realiza&#231;&#227;o tanto da cirurgia de <italic>by-pass</italic> g&#225;strico como da implanta&#231;&#227;o da banda g&#225;strica por via laparosc&#243;pica, t&#234;m demonstrado redu&#231;&#227;o significativa de sua preval&#234;ncia<sup>10-12</sup>.</p>
    <p>Apesar de preliminares, esses resultados sustentam a concep&#231;&#227;o de que a SM possa ser atenuada, ou mesmo revertida ap&#243;s a realiza&#231;&#227;o da cirurgia bari&#225;trica, permanecendo, no entanto, indefinido se esse efeito favor&#225;vel da cirurgia bari&#225;trica pode manter-se por tempo indeterminado. O presente estudo se prop&#245;e a confirmar em nosso meio o impacto favor&#225;vel da perda ponderal induzida pela cirurgia bari&#225;trica sobre a SM e pesquisar se esse benef&#237;cio se mant&#233;m em um per&#237;odo de observa&#231;&#227;o mais longo.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>A amostra objeto desta an&#225;lise foi constitu&#237;da por 35 pacientes submetidos &#224; deriva&#231;&#227;o gastrojejunal em Y de Roux anelada, via aberta (cirurgia bari&#225;trica), no per&#237;odo de outubro de 2001 a outubro de 2005, no Servi&#231;o de Cirurgia da Obesidade do nosso Hospital Universit&#225;rio (HU). Os pacientes eram predominantemente do sexo feminino (88,5%), com m&#233;dia de idade de 37,8&#177;11,1 anos, sendo 42,9% brancos, 11,4% negros e 45,7% pardos. Diagn&#243;sticos pr&#233;vios de hipertens&#227;o arterial e diabete melito foram observados em, respectivamente, 32,4% e 11,4% dos indiv&#237;duos. Constitu&#237;ram crit&#233;rios de exclus&#227;o a presen&#231;a de condi&#231;&#245;es cl&#237;nicas capazes de alterar os par&#226;metros para determina&#231;&#227;o da SM (gesta&#231;&#227;o, hipotireoidismo e tireotoxicose) e a ocorr&#234;ncia de &#243;bito, n&#227;o tendo sido verificados, no entanto, esses crit&#233;rios em nenhum paciente.</p>
    <p>Para o diagn&#243;stico da SM, foram adotados os crit&#233;rios do Programa Nacional de Educa&#231;&#227;o em Colesterol, dos Estados Unidos (<italic>National Cholesterol Education Program &#150; NCEP</italic>), contidos em seu 3&#186; relat&#243;rio<sup>13</sup>. De acordo com o NCEP, a SM &#233; diagnosticada se o paciente apresenta tr&#234;s ou mais dos seguintes par&#226;metros: obesidade abdominal (caracterizada por uma cintura abdominal &gt; 102 cm em homens e &gt; 88 cm em mulheres), eleva&#231;&#227;o da taxa sangu&#237;nea dos triglic&#233;rides ( <underline>&gt;</underline> 150 mg/dl), HDL-colesterol baixo (&lt; 40 mg/dl em homens e &lt; 50 mg/dl em mulheres), glicemia de jejum alterada ( <underline>&gt;</underline> 110 mg/dl) ou uso de antidiab&#233;ticos orais e press&#227;o arterial <underline>&gt;</underline> 130 x 85 mmHg ou uso de medicamentos anti-hipertensivos. </p>
    <p>Na primeira fase do estudo, foi preenchida ficha-protocolo contendo os dados demogr&#225;ficos e cl&#237;nico-antropom&#233;tricos, incluindo os crit&#233;rios adotados para o diagn&#243;stico da SM, de cada paciente, obtidos a partir das anota&#231;&#245;es contidas em prontu&#225;rio, antes da realiza&#231;&#227;o da cirurgia bari&#225;trica. A seguir, os pacientes operados foram convocados ambulatorialmente para obten&#231;&#227;o dos par&#226;metros necess&#225;rios para a identifica&#231;&#227;o da SM. Os exames laboratoriais adotados neste estudo foram realizados no Laborat&#243;rio Central de An&#225;lises Cl&#237;nicas do nosso HU. A preval&#234;ncia da SM no momento da reavalia&#231;&#227;o foi comparada &#224;quela verificada antes do procedimento cir&#250;rgico.</p>
    <p>Foi utilizado o programa Epi Info 2007 para a realiza&#231;&#227;o da an&#225;lise estat&#237;stica. As vari&#225;veis qualitativas foram representadas por frequ&#234;ncia relativa (%) e as vari&#225;veis cont&#237;nuas foram expressas como m&#233;dia e desvio padr&#227;o. O teste qui-quadrado foi utilizado para c&#225;lculo de signific&#226;ncia na compara&#231;&#227;o de propor&#231;&#245;es, e o de Wilcoxon, para as m&#233;dias. Foi adotado o n&#237;vel de signific&#226;ncia de 5% (p&lt;0,05).</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>No per&#237;odo basal, o &#237;ndice de massa corp&#243;rea (IMC) era de 44,9&#177;6,2 kg/m<sup>2</sup>, variando de 35,6 a 64,9 kg/m<sup>2</sup>, e a SM foi diagnosticada em 27 pacientes (77,1%). Em reavalia&#231;&#227;o 34,4&#177;15 meses depois da cirurgia, verificou-se uma queda do IMC para 28,3&#177;5,0 kg/m<sup>2</sup> (p=0,466), com varia&#231;&#227;o de 17,9 a 39,9 kg/m<sup>2</sup> , e a SM foi detectada em apenas dois pacientes (5,7%) (p&lt;0,001) (<xref ref-type="table" rid="tab01">tab.1</xref>). Portanto, para uma redu&#231;&#227;o m&#233;dia de 36,7% do IMC, ocorreu uma diminui&#231;&#227;o de 92,6% da preval&#234;ncia de SM.</p>
    <table-wrap id="tab01">
      <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gt01.jpg"/></table-wrap>
    <p>Dentre os crit&#233;rios diagn&#243;sticos de SM do NCEP, na an&#225;lise basal, os mais prevalentes foram cintura abdominal, presente em todos os pacientes, e HDL-colesterol baixo, observado em 27 pacientes (77,1%) (<xref ref-type="fig" rid="fig01">fig.1</xref>). Na reavalia&#231;&#227;o p&#243;s-cir&#250;rgica tardia, verificou-se redu&#231;&#227;o expressiva da preval&#234;ncia de todos os crit&#233;rios do NCEP (<xref ref-type="fig" rid="fig01">fig.1</xref>). A preval&#234;ncia dos crit&#233;rios cintura abdominal, glicemia, press&#227;o arterial, HDL-colesterol e triglicer&#237;deos foi reduzida em, respectivamente, 45,8%, 83%, 87,5%, 57,13% e 94% (<xref ref-type="fig" rid="fig02">fig.2</xref>). Cintura abdominal e HDL-colesterol baixo mantiveram-se como os crit&#233;rios mais prevalentes, sendo identificados em 54,3% e 34,3% dos pacientes, respectivamente, nesta reavalia&#231;&#227;o.</p>
    <fig id="fig01">
      <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gf01.jpg"/></fig>
    <fig id="fig02">
      <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gf02.jpg"/></fig>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Apesar de se tratar de uma popula&#231;&#227;o relativamente jovem, a SM mostrou-se altamente prevalente neste estudo, caracterizando um risco cardiovascular aumentado precocemente nesses indiv&#237;duos. Considerando-se as dificuldades habitualmente encontradas na perda ponderal por meio das medidas convencionais, a cirurgia bari&#225;trica apresenta-se na atualidade como um m&#233;todo muito eficiente para a indu&#231;&#227;o de perda ponderal importante e sustentada, em obesos m&#243;rbidos<sup>8</sup>. </p>
    <p>Existem evid&#234;ncias de que mesmo perdas ponderais pequenas, da ordem de 5% a 10% do peso, se traduzem em benef&#237;cios cl&#237;nicos significativos, como redu&#231;&#227;o da press&#227;o arterial e dos n&#237;veis glic&#234;micos<sup>14,15</sup>. A deriva&#231;&#227;o gastrojejunal em Y de Roux promove, em longo prazo, perdas de 35% a 40% do peso inicial<sup>16</sup>, sendo razo&#225;vel supor-se que essa perda ponderal mais intensa possa induzir a benef&#237;cios cl&#237;nicos ainda maiores. A pesquisa da SM, sabidamente associada a aumento independente de risco cardiovascular<sup>3</sup>, foi adotada neste estudo como uma maneira simples e objetiva de se avaliarem os benef&#237;cios da cirurgia bari&#225;trica. </p>
    <p>O efeito favor&#225;vel tanto da deriva&#231;&#227;o gastrojejunal em Y de Roux quanto da banda g&#225;strica ajust&#225;vel sobre a regress&#227;o da SM tem sido descrito em outras popula&#231;&#245;es, em seguimentos de at&#233; 12 meses<sup>10-12,17</sup>. Uma vez que fatores &#233;tnicos podem afetar a preval&#234;ncia de SM, n&#227;o era sabido se esses resultados poderiam ser extrapolados para a nossa popula&#231;&#227;o. Al&#233;m disso, n&#227;o estava claro se esse benef&#237;cio persistiria por tempo mais prolongado.</p>
    <p>Corroborando dados da literatura, a cirurgia bari&#225;trica, neste estudo, promoveu importante perda ponderal em m&#233;dio prazo (36,7%, em m&#233;dia). Como suposto, essa perda ponderal se traduziu em redu&#231;&#227;o altamente significativa da preval&#234;ncia de SM nessa popula&#231;&#227;o, de 92,6%, em reavalia&#231;&#227;o realizada, em m&#233;dia, tr&#234;s anos ap&#243;s o procedimento cir&#250;rgico. Observou-se diminui&#231;&#227;o acentuada da preval&#234;ncia de todos os cinco crit&#233;rios diagn&#243;sticos de SM do NCEP, com destaque para os crit&#233;rios glicemia, press&#227;o arterial e triglicer&#237;deos. Os crit&#233;rios cintura abdominal e HDL-colesterol mantiveram-se como os mais prevalentes na reavalia&#231;&#227;o tardia. </p>
    <p>Os benef&#237;cios observados ap&#243;s a realiza&#231;&#227;o da cirurgia bari&#225;trica podem dever-se n&#227;o apenas &#224; perda ponderal importante decorrente da restri&#231;&#227;o cal&#243;rica, mas tamb&#233;m &#224; mudan&#231;a do perfil da alimenta&#231;&#227;o proporcionada pela reeduca&#231;&#227;o alimentar, bem como &#224; ado&#231;&#227;o de uma vida mais ativa possibilitada pela perda de peso<sup>18,19</sup>. V&#225;rios estudos t&#234;m demonstrado que a obesidade, especialmente a adiposidade abdominal, tem papel decisivo na g&#234;nese da resist&#234;ncia insul&#237;nica, substrato fisiopatol&#243;gico das v&#225;rias manifesta&#231;&#245;es que comp&#245;em a SM<sup>20-22</sup>. Quaisquer que sejam os fatores determinantes e mecanismos envolvidos, a intensa melhora do perfil metab&#243;lico observada nesses pacientes sugere fortemente uma importante diminui&#231;&#227;o da resist&#234;ncia insul&#237;nica ou mesmo a sua revers&#227;o em alguns casos<sup>23</sup>.</p>
    <p>Por sua vez, alguns autores t&#234;m observado uma melhora acentuada ou mesmo cura do diabete melito tipo 2 muito precocemente ap&#243;s a realiza&#231;&#227;o da cirurgia bari&#225;trica, antes mesmo de haver perda significativa de peso, evocando poss&#237;veis mecanismos alternativos para justificar esse achado<sup>24-26</sup>.</p>
    <p>Recentemente tem sido reconhecida a import&#226;ncia das incretinas, pept&#237;deos produzidos pelo intestino, na fisiopatologia do diabete melito tipo 2. Essas subst&#226;ncias, representadas pelo GIP (<italic>gastric inhibitory peptide</italic>), secretado pelas c&#233;lulas K do intestino delgado proximal, e o GLP-1 (<italic>glucagon-like peptide-1</italic>), secretado pelas c&#233;lulas L do intestino delgado distal, t&#234;m sua secre&#231;&#227;o estimulada pelo contato com o bolo alimentar e, uma vez liberadas, atuam sobre o p&#226;ncreas estimulando a secre&#231;&#227;o de insulina. Ao GLP-1 tamb&#233;m t&#234;m sido atribu&#237;dos outros efeitos antidiabetog&#234;nicos, como o retardo do esvaziamento g&#225;strico, a diminui&#231;&#227;o do apetite, a inibi&#231;&#227;o do glucagon e a melhora da sensibilidade &#224; insulina. Diab&#233;ticos tipo 2 t&#234;m a secre&#231;&#227;o dessas subst&#226;ncias diminu&#237;da em resposta ao est&#237;mulo alimentar. Assim, tem-se postulado que a deriva&#231;&#227;o gastrojejunal em Y de Roux, ao promover aproxima&#231;&#227;o anat&#244;mica entre o est&#244;mago e o &#237;leo, possibilitando contado mais precoce do alimento com o intestino distal, acarretaria maior produ&#231;&#227;o de incretinas, justificando a melhora ou mesmo revers&#227;o do diabete melito tipo 2 por um mecanismo adicional independente da perda ponderal. De fato, pequenos estudos preliminares t&#234;m demonstrado incremento da secre&#231;&#227;o de incretinas precocemente ap&#243;s a realiza&#231;&#227;o da cirurgia bari&#225;trica, o que dever&#225; ser corroborado por estudos maiores futuros<sup>24-28</sup>.</p>
    <p>A pesquisa da SM, portanto, por sua alta preval&#234;ncia, conforme demonstrado, deve ser inclu&#237;da na avalia&#231;&#227;o rotineira de pacientes candidatos &#224; cirurgia bari&#225;trica. Pela facilidade dessa pesquisa na pr&#225;tica, contudo, ela deve ser adotada tamb&#233;m de forma sistem&#225;tica nas reavalia&#231;&#245;es de m&#233;dio e longo prazos como um importante par&#226;metro de benef&#237;cio da cirurgia bari&#225;trica nesses indiv&#237;duos. Trabalhos futuros poder&#227;o demonstrar se esse impacto favor&#225;vel da cirurgia bari&#225;trica sobre a SM &#233; capaz de promover efetivamente redu&#231;&#227;o da incid&#234;ncia de eventos cardiovasculares em longo prazo.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="end" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Francisco das Chagas Monteiro J&#250;nior </p>
        <p> Rua Santa Luzia, 27 QD.17, Quintas do Calhau </p>
        <p> 65067-460, S&#227;o Lu&#237;s, MA - Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="monteirojr@elo.com.br">monteirojr@elo.com.br</email>
        </p>
      </fn>
    </p>
    <p> Artigo recebido em 17/05/2008; revisado recebido em 19/06/2008; aceito em 09/07/2008.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Grundy SM. Metabolic syndrome: a multiplex    cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92 (2): 399-404.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic syndrome: a multiplex cardiovascular risk factor</article-title>
          <source>J Clin Endocrinol Metab</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>399</fpage>
          <lpage>404</lpage>
          <issue>2</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grundy</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Knopp RH. Drug treatment of lipid disorders.    N Engl J Med. 1999; 341: 498-511.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Drug treatment of lipid disorders</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>498</fpage>
          <lpage>511</lpage>
          <volume>341</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Knopp</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Wang J, Ruotsalainen S, Moilaren L, Lepisto    O, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality:    a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J. 2007;    28: 857-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>857</fpage>
          <lpage>64</lpage>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ruotsalainen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moilaren</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lepisto</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Laakso</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kuusisto</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Garrison RJ. Incidence and precursors of hypertension    in young adults: the Framinghan Offspring Study. Prev Med. 1987; 16: 234-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Incidence and precursors of hypertension in young adults: the Framinghan Offspring Study</article-title>
          <source>Prev Med</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>234</fpage>
          <lpage>51</lpage>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garrison</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Jung R. Obesity as a disease. Br Med Bull.    1997; 2 (53): 307-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Obesity as a disease</article-title>
          <source>Br Med Bull</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>307</fpage>
          <lpage>21</lpage>
          <issue>53</issue>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jung</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Hossain P, Kawar B, El Nahas M. Obesity and    diabetes in the developing world - a growing challenge. N Engl J Med. 2007;    356 (3): 213-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Obesity and diabetes in the developing world - a growing challenge</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>213</fpage>
          <lpage>5</lpage>
          <issue>3</issue>
          <volume>356</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hossain</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kawar</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>El Nahas</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Giri M. Medical management of obesity. Acta    Clin Belg. 2006; 61 (5): 286-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Medical management of obesity</article-title>
          <source>Acta Clin Belg</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>286</fpage>
          <lpage>94</lpage>
          <issue>5</issue>
          <volume>61</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Giri</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Brethauer SA, Chand B, Schauer PR. Risks and    benefits of bariatric surgery: current evidence. Clev Clin J Med. 2006; 73 (11):    993-1007.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Risks and benefits of bariatric surgery: current evidence</article-title>
          <source>Clev Clin J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>993</fpage>
          <lpage>1007</lpage>
          <issue>11</issue>
          <volume>73</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brethauer</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Chand</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schauer</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Sjostrom L, Narbro K, Sjostrom CDKarason K,    Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish    obese subjects. N Engl J Med. 2007; 357 (8): 741-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of bariatric surgery on mortality in Swedish obese subjects</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>741</fpage>
          <lpage>52</lpage>
          <issue>8</issue>
          <volume>357</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sjostrom</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Narbro</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sjostrom CDKarason</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Larsson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wedel</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Madan AK, Orth W, Ternovits CA, Tichansky    DS. Metabolic syndrome: yet another co-morbidity gastric bypass helps cure.    Surg Obes Relat Dis. 2006; 2: 48-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Metabolic syndrome: yet another co-morbidity gastric bypass helps cure</article-title>
          <source>Surg Obes Relat Dis</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>48</fpage>
          <lpage>51</lpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Madan</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Orth</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ternovits</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Tichansky</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Gazzaruso C. Weight loss after Swedish adjustable    gastric banding: relationships to insulin resistance and metabolic syndrome.    Obes Surg. 2002; 12: 841-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Weight loss after Swedish adjustable gastric banding: relationships to insulin resistance and metabolic syndrome</article-title>
          <source>Obes Surg</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>841</fpage>
          <lpage>5</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gazzaruso</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Giusti M. Effects of laparoscopic gastric    banding on body composition, metabolic profile and nutritional status of obese    women: 12-months follow-up. Obes Surg. 2004; 14: 239-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of laparoscopic gastric banding on body composition, metabolic profile and nutritional status of obese women: 12-months&#8217; follow-up</article-title>
          <source>Obes Surg</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>239</fpage>
          <lpage>45</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Giusti</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Executive Summary of the Third Report of    the National Cholesterol Education Program (NCEP). Expert Panel on Detection,    Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment    Panel III). JAMA. 2001; 285: 2486-97.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III)</article-title>
          <source>JAMA</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2486</fpage>
          <lpage>97</lpage>
          <volume>285</volume>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Willianson DF, Pamuk E, Thun M. Prospective    study of intentional weight loss and mortality in never-smoking over weight    US white women aged 40-64 years. Am J Epidemiol. 1995; 141: 1128-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prospective study of intentional weight loss and mortality in never-smoking over weight US white women aged 40-64 years</article-title>
          <source>Am J Epidemiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1128</fpage>
          <lpage>41</lpage>
          <volume>141</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Willianson</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Pamuk</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Thun</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Scheen AJ, Lef&#232;bvre PJ. Management    of the obese diabetic patient. Diab Rev. 1999; 7: 77-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Management of the obese diabetic patient</article-title>
          <source>Diab Rev</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>77</fpage>
          <lpage>93</lpage>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Scheen</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Lef&#232;bvre</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Garrido Jr AB. Situa&#231;&#245;es especiais:    tratamento da obesidade m&#243;rbida. In: Halpern A, Matos AFG, Suplicy HL,    Mancini MC. Obesidade. S&#227;o Paulo: Lemos Editorial; 1998. p. 331-41.</mixed-citation>
        <element-citation publication-type="book">
          <source>Obesidade</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>331</fpage>
          <lpage>41</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Garrido Jr</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Halpern</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matos</surname>
              <given-names>AFG</given-names>
            </name>
            <name>
              <surname>Suplicy</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Mancini</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Lee WJ. Effects of obesity surgery on the    metabolic syndrome. Arch Surg. 2004; 139: 1088-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of obesity surgery on the metabolic syndrome</article-title>
          <source>Arch Surg</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1088</fpage>
          <lpage>92</lpage>
          <volume>139</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>WJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Kelly TM, Jones SB. Changes in serum lipids    after gastric bypass surgery: lack of relationship to weight loss. Int J Obes.    1986; 10 (6): 443-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Changes in serum lipids after gastric bypass surgery: lack of relationship to weight loss</article-title>
          <source>Int J Obes</source>
          <date>
            <year>1986</year>
          </date>
          <fpage>443</fpage>
          <lpage>52</lpage>
          <issue>6</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kelly</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Bronstein MD. Exerc&#237;cio f&#237;sico    e obesidade. Rev Soc Cardiol Estado de S&#227;o Paulo. 1996; 6 (1): 111-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exerc&#237;cio f&#237;sico e obesidade</article-title>
          <source>Rev Soc Cardiol Estado de S&#227;o Paulo</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>111</fpage>
          <lpage>6</lpage>
          <issue>1</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism    in human obesity. Am J Physiol. 1994; 266 (4 Pt p): E600-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fat metabolism in human obesity</article-title>
          <source>Am J Physiol</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>E600</fpage>
          <lpage>5</lpage>
          <issue>4 Pt p</issue>
          <volume>266</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Campbell</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Nurjhan</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Lewis GF, Uffelman KD, Szeto LW, Steiner    G. Effects of acute hiperinsulinemia on VLDL triglyceride and VLDL ApoB production    in normal weight and obese individuals. Diabetes. 1993; 42 (6): 833-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of acute hiperinsulinemia on VLDL triglyceride and VLDL ApoB production in normal weight and obese individuals</article-title>
          <source>Diabetes</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>833</fpage>
          <lpage>42</lpage>
          <issue>6</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lewis</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Uffelman</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Szeto</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Malmstrom R, Packard CJ, Caslake M, Bedford    D, Stewart P, Yki-J&#228;rvinen H, et al. Defective regulation of triglyceride    metabolism by insulin in the liver in NIDDM. Diabetologia. 1997; 40 (4): 454-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM</article-title>
          <source>Diabetologia</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>454</fpage>
          <lpage>62</lpage>
          <issue>4</issue>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Malmstrom</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Packard</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Caslake</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bedford</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Yki-J&#228;rvinen</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Swenson TL. The role of the cholesteryl ester    transfer protein in lipoprotein metabolism. Diabetes Metab Rev. 1991; 7 (3):    139-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The role of the cholesteryl ester transfer protein in lipoprotein metabolism</article-title>
          <source>Diabetes Metab Rev</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>139</fpage>
          <lpage>53</lpage>
          <issue>3</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Swenson</surname>
              <given-names>TL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Lamounier RN, Pareja JC, Tambascia MA, Geloneze    B. Incretins: clinical physiology and bariatric surgery  correlating the entero-endocrine    system and a potentially anti-dysmetabolic procedure. Diabetes Care. 2007; 30    (7): 1709-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Incretins: clinical physiology and bariatric surgery - correlating the entero-endocrine system and a potentially anti-dysmetabolic procedure</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1709</fpage>
          <lpage>16</lpage>
          <issue>7</issue>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lamounier</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Pareja</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Tambascia</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Geloneze</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Buchwald H, Avidor Y, Braunwald E, Jensen    MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and    meta-analysis. JAMA. 2004; 292: 1724-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Bariatric surgery: a systematic review and meta-analysis</article-title>
          <source>JAMA</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1724</fpage>
          <lpage>37</lpage>
          <volume>292</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Buchwald</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Avidor</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Pories</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Fahrbach</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Pories WJ, MacDonald KG, Morgan EJ, Sinha    MK, Dohm GL, Swanson MS, et al. Surgical treatment of obesity and its effect    on diabetes: 10-y follow-up. Am J Clin Nutr. 1992; 55 (2 Suppl): 5825-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Surgical treatment of obesity and its effect on diabetes: 10-y follow-up</article-title>
          <source>Am J Clin Nutr</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>5825</fpage>
          <lpage>55</lpage>
          <volume>55</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pories</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>MacDonald</surname>
              <given-names>KG</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Dohm</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Swanson</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Frezza EE. Are we closer to finding the treatment    for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to    success? Obes Surg. 2004; 14: 999-1005.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Are we closer to finding the treatment for type 2 diabetes mellitus in morbid obesity? Are the incretins the key to success?</article-title>
          <source>Obes Surg</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>999</fpage>
          <lpage>1005</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Frezza</surname>
              <given-names>EE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Laferr&#232;re B, Heshka S, Wang K, Khan    Y, McGinty J, Teixeira J, et al. Incretin levels and effect are markedly enhanced    1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2    diabetes. Diabetes Care. 2007; 30: 1709-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes</article-title>
          <source>Diabetes Care</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1709</fpage>
          <lpage>16</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Laferr&#232;re</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Heshka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>McGinty</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Teixeira</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Efecto de la p&#233;rdida ponderal inducida por la cirug&#237;a bari&#225;trica sobre la prevalencia de s&#237;ndrome metab&#243;lico</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El s&#237;ndrome metab&#243;lico (SM) frecuentemente est&#225; vinculado al exceso de peso y mejora con la p&#233;rdida ponderal, esper&#225;ndose que esta mejora sea proporcional a la intensidad de esa p&#233;rdida. OBJETIVO: Evaluar el impacto de la p&#233;rdida ponderal inducida por la cirug&#237;a bari&#225;trica (CB) sobre la prevalencia de la SM, a medio plazo. M&#201;TODOS: Se estudiaron 35 pacientes sometidos a cirug&#237;a de bypass gastroyeyunal en Y de Roux, en el per&#237;odo de octubre de 2001 a octubre de 2005, en nuestro HU, siendo el 88,5% del sexo femenino, con un promedio de edades de 37,8&#177;11,1 a&#241;os y un IMC promedio de 45,0&#177;6,2 Kg/m&#178;. En la primera etapa de la investigaci&#243;n, se obtuvieron datos demogr&#225;ficos y cl&#237;nico antropom&#233;tricos antes de la realizaci&#243;n de la CB, incluyendo los criterios para el diagn&#243;stico de la SM, de acuerdo con las directrices del NCEP de los Estados Unidos. En la segunda etapa, los pacientes operados se reevaluaron ambulatoriamente con relaci&#243;n a la prevalencia de la SM. RESULTADOS: Antes de la cirug&#237;a, fue diagnostica la SM en 27 pacientes (77,1%). En la reevaluaci&#243;n 34,4&#177;15 meses despu&#233;s de la cirug&#237;a, se observ&#243; una disminuci&#243;n del IMC promedio para 28,3&#177;5,0 Kg/m&#178; y se detecto la SM s&#243;lo en dos pacientes (5,7%) (p&lt;0,001). La prevalencia de los criterios cintura abdominal, glicemia, presi&#243;n arterial, HDL-colesterol y triglic&#233;ridos, se redujeron respectivamente en: 45,8%, 83%, 87,5%, 57,13% y 94%. CONCLUSI&#211;N: La SM es com&#250;n en obsesos candidatos a CB y este procedimiento se mostr&#243; extremadamente eficaz en la inducci&#243;n de la regresi&#243;n del s&#237;ndrome, verific&#225;ndose una reducci&#243;n expresiva de la prevalencia de todos los criterios del NCEP.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>S&#237;ndrome metab&#243;lico</kwd>
        <kwd>prevalencia</kwd>
        <kwd>obesidad</kwd>
        <kwd>cirug&#237;a bari&#225;trica</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="tx-body2"/>Efecto de la p&#233;rdida ponderal inducida por la cirug&#237;a bari&#225;trica sobre la prevalencia de s&#237;ndrome metab&#243;lico</p>
      <p>
        <bold>Francisco das Chagas Monteiro J&#250;nior; Wellington Santana da Silva J&#250;nior; Natalino Salgado Filho; Pedro Ant&#244;nio Muniz Ferreira; Gutenberg Fernandes Ara&#250;jo; Nat&#225;lia Ribeiro Mandarino; Jos&#233; Bonif&#225;cio Barbosa; Joyce Santos Lages; Jos&#233; de Ribamar Oliveira Lima; Carolina Cipriano Monteiro </bold>
      </p>
      <p>Hospital Universitario de la Universidad Federal de Maranh&#227;o, S&#227;o Lu&#237;s, MA - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> El s&#237;ndrome metab&#243;lico (SM) frecuentemente est&#225; vinculado al exceso de peso y mejora con la p&#233;rdida ponderal, esper&#225;ndose que esta mejora sea proporcional a la intensidad de esa p&#233;rdida.</p>
      <p><bold>OBJETIVO:</bold> Evaluar el impacto de la p&#233;rdida ponderal inducida por la cirug&#237;a bari&#225;trica (CB) sobre la prevalencia de la SM, a medio plazo.</p>
      <p><bold>M&#201;TODOS:</bold> Se estudiaron 35 pacientes sometidos a cirug&#237;a de bypass gastroyeyunal en Y de Roux, en el per&#237;odo de octubre de 2001 a octubre de 2005, en nuestro HU, siendo el 88,5% del sexo femenino, con un promedio de edades de 37,8&#177;11,1 a&#241;os y un IMC promedio de 45,0&#177;6,2 Kg/m<sup>2</sup>. En la primera etapa de la investigaci&#243;n, se obtuvieron datos demogr&#225;ficos y cl&#237;nico antropom&#233;tricos antes de la realizaci&#243;n de la CB, incluyendo los criterios para el diagn&#243;stico de la SM, de acuerdo con las directrices del NCEP de los Estados Unidos. En la segunda etapa, los pacientes operados se reevaluaron ambulatoriamente con relaci&#243;n a la prevalencia de la SM.</p>
      <p><bold>RESULTADOS:</bold> Antes de la cirug&#237;a, fue diagnostica la SM en 27 pacientes (77,1%). En la reevaluaci&#243;n 34,4&#177;15 meses despu&#233;s de la cirug&#237;a, se observ&#243; una disminuci&#243;n del IMC promedio para 28,3&#177;5,0 Kg/m<sup>2</sup> y se detecto la SM s&#243;lo en dos pacientes (5,7%) (p&lt;0,001). La prevalencia de los criterios cintura abdominal, glicemia, presi&#243;n arterial, HDL-colesterol y triglic&#233;ridos, se redujeron respectivamente en: 45,8%, 83%, 87,5%, 57,13% y 94%.</p>
      <p><bold>CONCLUSI&#211;N:</bold> La SM es com&#250;n en obsesos candidatos a CB y este procedimiento se mostr&#243; extremadamente eficaz en la inducci&#243;n de la regresi&#243;n del s&#237;ndrome, verific&#225;ndose una reducci&#243;n expresiva de la prevalencia de todos los criterios del NCEP.</p>
      <p><bold>Palabras clave:</bold> S&#237;ndrome metab&#243;lico , prevalencia, obesidad, cirug&#237;a bari&#225;trica.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>El t&#233;rmino s&#237;ndrome metab&#243;lico (SM) describe una condici&#243;n que ocurre predominantemente en pa&#237;ses civilizados y cuyas manifestaciones m&#225;s prominentes son la obesidad androide (abdominal), la diabetes mellitus tipo 2, la hipertensi&#243;n arterial y des&#243;rdenes del metabolismo de los l&#237;pidos, que se traducen especialmente en la presencia de part&#237;culas de LDL-colesterol peque&#241;as y densas, HDL-colesterol bajo y elevaci&#243;n de la tasa de triglic&#233;ridos en la sangre. Se estima que la SM afecta a cerca del 20% al 30% de la poblaci&#243;n en edad media y avanzada<sup>1,2</sup>. Su mayor importancia reside en el hecho de que est&#225; implicada con un aumento significativo del riesgo de morbilidad y mortalidad cardiovascular<sup>3</sup>.</p>
      <p>Se cree que la obesidad, especialmente la adiposidad abdominal, sea de fundamental importancia en el desarrollo del s&#237;ndrome, mediante la inducci&#243;n de la resistencia a la insulina, disturbio se&#241;alado como desencadenante de otras alteraciones descritas<sup>1</sup>. Estudios epidemiol&#243;gicos demuestran que el exceso de peso responde por un 78% de los casos de hipertensi&#243;n en hombres y un 65% de los casos en mujeres<sup>4</sup>, as&#237; como aumenta el riesgo de ocurrencia de diabetes mellitus tipo 2 en 10 veces<sup>5</sup>. Un &#237;ndice de masa corporal &gt; 35 Kg/m<sup>2</sup> aumenta el riesgo de desarrollar diabetes mellitus en 93 veces en hombres y 42 veces en mujeres<sup>5</sup>. Estos datos son bastante alarmantes, puesto que la prevalencia de obesidad ha venido aumentando en forma descontrolada en pa&#237;ses industrializados<sup>6</sup>. </p>
      <p>Los beneficios de la reducci&#243;n ponderal obtenida a partir de cambios en el estilo de vida, como la adopci&#243;n de dieta hipocal&#243;rica y la pr&#225;ctica de actividad f&#237;sica, est&#225;n ampliamente documentados<sup>7</sup>. En portadores de obesidad m&#243;rbida, resistente a medidas conservadoras, la cirug&#237;a de reducci&#243;n de est&#243;mago (cirug&#237;a bari&#225;trica) ha proporcionado en los &#250;ltimos a&#241;os p&#233;rdidas ponderales importantes en estos individuos, con la consiguiente mejora de las comorbilidades y de la calidad de vida<sup>8</sup>.</p>
      <p>El estudio <italic>Swedish Obese Subjects</italic> (SOS), publicado recientemente, que realiz&#243; el seguimiento de 4.047 obesos durante 10 a&#241;os, 2.010 de los cuales fueron sometidos a cirug&#237;a bari&#225;trica y 2.037 mantenidos bajo tratamiento convencional (grupo de control), mostr&#243; una tasa de mortalidad por todas las causas, menor en el grupo quir&#250;rgico. A pesar de no ser aleatorio, este ensayo trajo una importante evidencia adicional acerca de la seguridad y beneficio de la cirug&#237;a bari&#225;trica<sup>9</sup>.</p>
      <p>Espec&#237;ficamente con relaci&#243;n a la SM, peque&#241;os estudios iniciales, con seguimiento de hasta un a&#241;o despu&#233;s de la realizaci&#243;n tanto de la cirug&#237;a de <italic>bypass</italic> g&#225;strico como de la implantaci&#243;n de la banda g&#225;strica por v&#237;a laparosc&#243;pica, demostr&#243; una reducci&#243;n significativa de su prevalencia<sup>10-12</sup>.</p>
      <p>A pesar de preliminares, estos estudios sustentan la concepci&#243;n de que la SM pueda ser atenuada, o incluso revertida tras la realizaci&#243;n de la cirug&#237;a bari&#225;trica, permaneciendo, sin embargo, indefinido el aspecto de si este efecto favorable de la cirug&#237;a bari&#225;trica puede mantenerse por tiempo indeterminado. El presente estudio se propone confirmar en nuestro medio el impacto favorable de la p&#233;rdida ponderal inducida por cirug&#237;a bari&#225;trica sobre la SM e investigar si este beneficio se mantiene en un per&#237;odo de observaci&#243;n m&#225;s largo.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>La muestra objeto de este an&#225;lisis estuvo constituida por 35 pacientes sometidos a derivaci&#243;n gastroyeyunal en Y de Roux anillada, v&#237;a abierta (cirug&#237;a bari&#225;trica), en el per&#237;odo de octubre 2001 a octubre de 2005, en el Servicio de Cirug&#237;a de Obesidad en nuestro Hospital Universitario (HU). Los pacientes eran predominantemente del sexo femenino (88,5%), con un promedio de edades de 37,8&#177;11,1 a&#241;os, siendo 42,9% blancos, 11,4% negros y 45,7% pardos. Diagn&#243;sticos previos de hipertensi&#243;n arterial y diabetes mellitus se observaron en, respectivamente, un 32,4% y un 11,4% de los individuos. Constituyeron criterios de exclusi&#243;n la presencia de condiciones cl&#237;nicas capaces de alterar los par&#225;metros para determinaci&#243;n de la SM (gestaci&#243;n, hipotiroidismo y tirotoxicosis) y la ocurrencia de &#243;bito, no siendo verificados, con todo, estos criterios en ning&#250;n paciente.</p>
      <p>Para el diagn&#243;stico de la SM se adoptaron los criterios del Programa Nacional de Educaci&#243;n en Colesterol, de los Estados Unidos (<italic>National Cholesterol Education Program</italic> - NCEP), contenidos en su 3&#186; informe<sup>13</sup>. De acuerdo con el NCEP, se diagnostica el SM si el paciente presenta tres o m&#225;s de los siguientes par&#225;metros: obesidad abdominal (caracterizada por cintura abdominal &gt; 102 cm en hombres y &gt; 88 cm en mujeres), elevaci&#243;n de la tasa sangu&#237;nea de los triglic&#233;ridos (<underline>&gt;</underline> 150 mg/dl), HDL-colesterol bajo (&lt; 40 mg/dl en hombres y &lt; 50 mg/dl en mujeres), glicemia en ayunas alterada (<underline>&gt;</underline> 110 mg/dl) o uso de antidiab&#233;ticos orales y presi&#243;n arterial <underline>&gt;</underline> 130 x 85 mmHg o uso de medicamentos antihipertensivos. </p>
      <p>En la primera fase del estudio se complet&#243; una ficha protocolo conteniendo los datos demogr&#225;ficos y cl&#237;nico antropom&#233;tricos, incluyendo los criterios adoptados para el diagn&#243;stico del SM, de cada paciente, obtenidos a partir de las anotaciones contenidas en la historia cl&#237;nica, antes de realizar la cirug&#237;a bari&#225;trica A continuaci&#243;n, los pacientes operados fueron convocados ambulatoriamente para obtener los par&#225;metros necesarios para la identificaci&#243;n del SM. Los ex&#225;menes de laboratorio adoptados en este estudio fueron realizados en el Laboratorio Central de An&#225;lisis Cl&#237;nicos de nuestro HU. La prevalencia del SM al momento de la reevaluaci&#243;n fue comparada a la verificada antes del procedimiento quir&#250;rgico.</p>
      <p>Se utiliz&#243; el programa Epi Info 2007 para la realizaci&#243;n del an&#225;lisis estad&#237;stico. Las variables cualitativas fueron representadas por frecuencia relativa (%) y las variables continuas se expresaron como promedio y desviaci&#243;n est&#225;ndar. Se utiliz&#243; el test chi-cuadrado para el c&#225;lculo de significancia en la comparaci&#243;n de proporciones, y el de Wilcoxon, para los promedios. Se adopt&#243; el nivel de significancia de 5% (p&lt;0,05).</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>En el per&#237;odo basal, el &#237;ndice de masa corporal (IMC) era de 44,9&#177;6,2 Kg/m<sup>2</sup>, variando de 35,6 a 64,9 Kg/m<sup>2</sup>, y el SM fue diagnosticado en 27 pacientes (77,1%). En reevaluaci&#243;n 34,4&#177;15 meses despu&#233;s de la cirug&#237;a, se verific&#243; una disminuci&#243;n del IMC para 28,3&#177;5,0 Kg/m<sup>2</sup> (p=0,466), con variaci&#243;n de 17,9 a 39,9 Kg/m<sup>2</sup> , y el SM fue detectado s&#243;lo en dos pacientes (5,7%) (p&lt;0,001) (<xref ref-type="table" rid="tab01-body2">tab.1</xref>). Por lo tanto, para una reducci&#243;n promedio del 36,7% del IMC, hubo una disminuci&#243;n del 92,6% de la prevalencia de SM.</p>
      <table-wrap id="tab01-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gt01-es.jpg"/></table-wrap>
      <p>Entre los criterios de diagn&#243;stico de SM del NCEP, en el an&#225;lisis basal, los m&#225;s predominantes fueron la cintura abdominal, presente en todos los pacientes, y el HDL-colesterol bajo, observado en 27 pacientes (77,1%) (<xref ref-type="fig" rid="fig01-body2">fig.1</xref>). En la reevaluaci&#243;n post quir&#250;rgica tard&#237;a, ser verific&#243; una expresiva reducci&#243;n de la prevalencia de todos los criterios del NCEP (<xref ref-type="fig" rid="fig01-body2">fig.1</xref>). La prevalencia de los criterios cintura abdominal, glicemia, presi&#243;n arterial, HDL-colesterol y triglic&#233;ridos, se redujeron respectivamente en: 45,8%, 83%, 87,5%, 57,13% y 94% (<xref ref-type="fig" rid="fig02-body2">fig. 2</xref>). Cintura abdominal y HDL-colesterol bajo se mantuvieron como los criterios predominantes, siendo identificados en el 54,3% y el 34,3% de los pacientes, respectivamente, en esta reevaluaci&#243;n.</p>
      <fig id="fig01-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gf01-es.jpg"/></fig>
      <fig id="fig02-body2">
        <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gf02-es.jpg"/></fig>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>A pesar de tratarse de una poblaci&#243;n relativamente joven, el SM se mostr&#243; altamente predominante en este estudio, caracterizando un riesgo cardiovascular aumentado precozmente en estos individuos. Considerando las dificultades habitualmente encontradas en la p&#233;rdida ponderal por medio de las medidas convencionales, la cirug&#237;a bari&#225;trica se presenta en la actualidad como un m&#233;todo muy eficiente para la inducci&#243;n de p&#233;rdida ponderal importante y sostenida, en obesos m&#243;rbidos<sup>8</sup>.</p>
      <p>Hay evidencias de que incluso peque&#241;as p&#233;rdidas ponderales, del orden del 5% al 10% del peso, se traducen en beneficios cl&#237;nicos significativos, como reducci&#243;n de la presi&#243;n arterial y de los niveles glic&#233;micos<sup>14,15</sup>. La derivaci&#243;n gastroyeyunal en Y de Roux promueve, en el largo plazo, p&#233;rdidas del 35% al 40% del peso inicial<sup>16</sup>, siendo razonable suponer que una p&#233;rdida ponderal m&#225;s intensa pueda inducir a beneficios cl&#237;nicos aun mayores. La investigaci&#243;n del SM, conocidamente asociado al aumento independiente de riesgo cardiovascular<sup>3</sup>, fue adoptada en este estudio como una forma simple y objetiva de evaluar los beneficios de la cirug&#237;a bari&#225;trica.</p>
      <p>El efecto favorable tanto de la derivaci&#243;n gastroyeyunal en Y de Roux como de la banda g&#225;strica ajustable sobre la regresi&#243;n del SM fue descrito en otras poblaciones, en seguimientos de hasta 12 meses<sup>10-12,17</sup>. Puesto que factores &#233;tnicos pueden afectar la prevalencia de SM, no se sab&#237;a si estos resultados podr&#237;an ser extrapolados para nuestra poblaci&#243;n. Adem&#225;s de ello, no estaba claro si este beneficio persistir&#237;a por un tiempo m&#225;s prolongado.</p>
      <p>Corroborando datos de la bibliograf&#237;a, la cirug&#237;a bari&#225;trica, en este estudio, promovi&#243; una importante p&#233;rdida ponderal en el medio plazo (36,7%, en promedio). Como se supon&#237;a, esta p&#233;rdida ponderal se tradujo en una reducci&#243;n altamente significativa de la prevalencia de SM en esa poblaci&#243;n, del 92,6%, en reevaluaci&#243;n realizado, en promedio, tres a&#241;os despu&#233;s del procedimiento quir&#250;rgico. Se observ&#243; una disminuci&#243;n acentuada de la prevalencia de los cinco criterios diagn&#243;sticos de SM del NCEP, con destaque para los criterios glicemia, presi&#243;n arterial y triglic&#233;ridos. Los criterios cintura abdominal y HDL-colesterol se mantuvieron como los m&#225;s predominantes en la reevaluaci&#243;n tard&#237;a. </p>
      <p>Los beneficios observados tras la realizaci&#243;n de la cirug&#237;a bari&#225;trica pueden deberse no s&#243;lo a la p&#233;rdida ponderal importante derivada de la restricci&#243;n cal&#243;rica, sino tambi&#233;n al cambio en el perfil de la alimentaci&#243;n proporcionada por la reeducaci&#243;n alimentaria, as&#237; como la adopci&#243;n de una vida m&#225;s activa posibilitada por la p&#233;rdida peso<sup>18,19</sup>. Varios estudios demuestran que la obesidad, especialmente la adiposidad abdominal, tiene un papel decisivo en la g&#233;nesis de la resistencia insul&#237;nica, sustrato fisiopatol&#243;gico de varias manifestaciones que componen el SM<sup>20-22</sup>. Cualquiera que sean los factores determinantes y mecanismos involucrados, la intensa mejora del perfil metab&#243;lico observada en esos pacientes sugiere fuertemente una importante disminuci&#243;n de la resistencia insul&#237;nica o incluso su reversi&#243;n en algunos casos<sup>23</sup>.</p>
      <p>A su vez, algunos autores observaron una mejora acentuada o incluso la cura de diabetes mellitus tipo 2 muy precozmente, despu&#233;s de la realizaci&#243;n de la cirug&#237;a bari&#225;trica, antes incluso de ocurrir una p&#233;rdida significativa de peso, evocando posibles mecanismos alternativos para justificar este hallazgo<sup>24-26</sup>.</p>
      <p>Recientemente ha sido reconocida la importancia de las incretinas, p&#233;ptidos producidos por el intestino, en la fisiopatolog&#237;a de la diabetes mellitus tipo 2. Estas sustancias, representadas por el GIP (gastric inhibitory peptide), secretado por las c&#233;lulas K del intestino delgado proximal, y el GLP-1 (glucagon-like peptide-1), secretado por las c&#233;lulas L del intestino delgado distal, tiene su secreci&#243;n estimulada por el contacto con el bolo alimenticio y, una vez liberadas, act&#250;an sobre el p&#225;ncreas estimulando la secreci&#243;n de insulina. Al GLP-1 tambi&#233;n se le han atribuido otros efectos antidiabetog&#233;nicos, como el retraso en el vaciado g&#225;strico, la disminuci&#243;n del apetito, la inhibici&#243;n del glucag&#243;n y la mejora de la sensibilidad a la insulina. Diab&#233;ticos tipo 2 presentan una disminuci&#243;n en la secreci&#243;n de estas sustancias en respuesta al est&#237;mulo alimentario. En raz&#243;n de ello, se ha postulado que la derivaci&#243;n gastroyeyunal en Y de Roux, al promover una aproximaci&#243;n anat&#243;mica entre el est&#243;mago y el &#237;leo, posibilitando un contacto m&#225;s precoz del alimento con el intestino distal, conllevar&#237;a a una mayor producci&#243;n de incretinas, justificando la mejora o incluso la reversi&#243;n de la diabetes mellitus tipo 2 por un mecanismo adicional independiente de la p&#233;rdida ponderal. De hecho, peque&#241;os estudios preliminares han demostrado un incremento en la secreci&#243;n de incretinas precozmente, despu&#233;s de la realizaci&#243;n de la cirug&#237;a bari&#225;trica, lo que deber&#225; ser corroborado por estudios mayores futuros<sup>24-28</sup>.</p>
      <p>La investigaci&#243;n del SM, por tanto, por su alta prevalencia, como se demostr&#243;, debe incluirse en la evaluaci&#243;n rutinaria de pacientes candidatos a cirug&#237;a bari&#225;trica. Por la facilidad de esta investigaci&#243;n en la pr&#225;ctica, con todo, &#233;sta debe adoptarse tambi&#233;n de forma sistem&#225;tica en reevaluaciones de medio y largo plazo como importante par&#225;metro de beneficio de la cirug&#237;a bari&#225;trica en esos individuos. Futuros trabajos podr&#225;n demostrar si este impacto favorable de la cirug&#237;a bari&#225;trica sobre el SM es capaz de promover efectivamente una reducci&#243;n de la incidencia de episodios cardiovasculares a largo plazo.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiamiento externas.</p>
      <p>
        <bold>V&#237;nculo Acad&#233;mico</bold>
      </p>
      <p>No hay v&#237;nculo de este estudio a programas de post grado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Effects of weight loss induced by bariatric surgery on the prevalence of metabolic syndrome</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Metabolic Syndrome (MS) is often linked to overweight/obesity and can improve after weight loss, such improvement is expected to be proportional to the intensity of weight loss. OBJECTIVE: The aim of this study was to evaluate the impact of weight loss induced by bariatric surgery (BS) on the prevalence of MS in a middle-term period. METHODS: Thirty-five (35) patients who underwent surgical Roux's Y gastrojejunal by-pass from October 2001 until October 2005 in our University Hospital were evaluated. 88.5% were female, with a mean age at the time of surgery of 37.8&#177;11.1 years and a mean BMI of 45.0&#177;6.2 Kg/m&#178;. During the first stage of our study demographic and clinical-anthropomorphic data were collected prior to the BC procedure, including those criteria needed for the diagnosis of MS, according to the guidelines of the US NCEP. The second stage consisted of reevaluation of those patients in the post-surgical period in order to determine the prevalence of MS in an outpatient setting. RESULTS: Prior to surgery, MS was diagnosed in 27 patients (77.1%). When those patients were reevaluated 34.4&#177;15 months after surgery, a reduction of mean BMI to 28.3&#177;5.0 Kg/m&#178; and MS was identified in only two patients (5.7%) (p&lt;0.001). Prevalence of individual criteria such as abdominal circumference, fasting glucose levels, arterial blood pressure, HDL-cholesterol and triglycerides had a reduction of 45.8%, 83%, 87.5%, 57.13% and 94% respectively. CONCLUSION: MS is a rather common feature in obese patients enrolled for BS and this procedure has been proved to be extremely efficient reversing the metabolic syndrome, with an expressive reduction of prevalence of each and all of the NCEP criteria.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Metabolic syndrome</kwd>
        <kwd>prevalence</kwd>
        <kwd>obesity</kwd>
        <kwd>bariatric surgery</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="tx-body3">
          <label>
            <bold>Effects of weight loss induced by bariatric surgery on the prevalence of metabolic syndrome</bold>
          </label>
          <p>
            <bold>Francisco das Chagas Monteiro J&#250;nior; Wellington Santana da Silva J&#250;nior; Natalino Salgado Filho; Pedro Ant&#244;nio Muniz Ferreira; Gutenberg Fernandes Ara&#250;jo; Nat&#225;lia Ribeiro Mandarino; Jos&#233; Bonif&#225;cio Barbosa; Joyce Santos Lages; Jos&#233; de Ribamar Oliveira Lima; Carolina Cipriano Monteiro</bold>
          </p>
        </fn>
      </p>
      <p>Hospital Universit&#225;rio da Universidade Federal do Maranh&#227;o, S&#227;o Lu&#237;s, MA - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Metabolic Syndrome (MS) is often linked to overweight/obesity and can improve after weight loss, such improvement is expected to be proportional to the intensity of weight loss.</p>
      <p><bold>OBJECTIVE:</bold> The aim of this study was to evaluate the impact of weight loss induced by bariatric surgery (BS) on the prevalence of MS in a middle-term period.</p>
      <p><bold>METHODS:</bold> Thirty-five (35) patients who underwent surgical Roux's Y gastrojejunal by-pass from October 2001 until October 2005 in our University Hospital were evaluated. 88.5% were female, with a mean age at the time of surgery of 37.8&#177;11.1 years and a mean BMI of 45.0&#177;6.2 Kg/m<sup>2</sup>. During the first stage of our study demographic and clinical-anthropomorphic data were collected prior to the BC procedure, including those criteria needed for the diagnosis of MS, according to the guidelines of the US NCEP. The second stage consisted of reevaluation of those patients in the post-surgical period in order to determine the prevalence of MS in an outpatient setting.</p>
      <p><bold>RESULTS:</bold> Prior to surgery, MS was diagnosed in 27 patients (77.1%). When those patients were reevaluated 34.4&#177;15 months after surgery, a reduction of mean BMI to 28.3&#177;5.0 Kg/m<sup>2</sup> and MS was identified in only two patients (5.7%) (p&lt;0.001). Prevalence of individual criteria such as abdominal circumference, fasting glucose levels, arterial blood pressure, HDL-cholesterol and triglycerides had a reduction of 45.8%, 83%, 87.5%, 57.13% and 94% respectively.</p>
      <p><bold>CONCLUSION:</bold> MS is a rather common feature in obese patients enrolled for BS and this procedure has been proved to be extremely efficient reversing the metabolic syndrome, with an expressive reduction of prevalence of each and all of the NCEP criteria.</p>
      <p><bold>Key words:</bold> Metabolic syndrome; prevalence; obesity; bariatric surgery.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>The term metabolic syndrome (MS) is used to describe a disorder that is more prevalent in the so-called civilized countries and whose manifestations are android (abdominal) obesity, diabetes mellitus type 2, arterial hypertension and disorders of lipid metabolism that can be summarized as the occurrence of small and dense LDL-cholesterol particles, low levels of HDL-cholesterol and elevated serum levels of triglycerides. An estimated 20% up to 30% of middle aged and elderly population is affected by MS<sup>1,2</sup>. Its importance remains in its association with a significant increase in the risk of morbidity obesity and cardiovascular mortality<sup>3</sup>.</p>
      <p>Obesity, especially abdominal adiposity, may be fundamental for the development of the syndrome by inducing peripheral resistance to insulin, which, in turn, seems to quick-start the development of the other disorders previously described<sup>1</sup>. Epidemiological studies have shown that overweight is responsible for 78% of the cases of hypertension in male patients and for 65% of females<sup>4</sup>, as well as an elevation of the risk of developing diabetes mellitus type 2 10 times higher than in non-obese subjects<sup>5</sup>. Furthermore, a body index &gt; 35 Kg/m<sup>2</sup> elevates the risk of developing diabetes mellitus 93 times in male subjects and 42 times in females<sup>5</sup>. These are quite alarming data, as the prevalence of obesity has increased unchecked in the developed countries<sup>6</sup>. </p>
      <p>The benefits of changes of live style, such as following a hypocaloric diet and regular sport activity, resulting in weight loss have been extensively documented<sup>7</sup>. In those persons who have morbid obesity refractory clinical measures, surgical stomach reduction (bariatric surgery) has allowed them to loose weight in significant amounts, with subsequent increase in quality of life and an overall improvement of comorbities<sup>8</sup>. </p>
      <p> The Swedish Obese Subjects (SOS) study, which has been published recently, followed 4,047 obese subjects for 10 years, with 2,010 subjects undergoing bariatric surgery and the remaining 2,037 following conventional clinical treatment (control group), demonstrated that mortality rates for each individual cause were smaller in the surgical group. Although this study was non-randomized, it provided additional evidence regarding safety issues and benefits of bariatric surgery <sup>9</sup>.</p>
      <p>Specifically regarding MS, small initial studies with a follow-up period of up to one year after laparoscopic gastric <italic>by-pass</italic> or adjustable gastric banding have showed a significant reduction of its prevalence<sup>10-12</sup>.</p>
      <p>Despite the fact that these are all preliminary studies, these results provide adequate support to the hypothesis that MS might be attenuated, or ever reverted, after bariatric surgery. However, it is unknown whether the favorable effects of bariatric surgery may persist for an indeterminate period. Our study aims are to confirm in our population the favorable impact of significant weight loss induced by bariatric surgery on MS, as well as to see for how long these benefic results remain unchanged in a longer follow-up period. </p>
      <p>
        <bold>Method</bold>
      </p>
      <p>The studied sample was made of 35 patients who underwent Roux's Y gastrojejunal <italic>by-pass</italic> through open surgery (Bariatric Surgery), from October 2001 until October 2005, at the Obesity Surgery Service of our Universitary Hospital (UH). Patients were mostly female (88.5%), with a mean age at the time of surgery of 37.8&#177;11.1 years, 42.9% were Caucasian, 11.4% were black (African-Brazilian) and the remaining 45.7% were had a mixed ethnic background. Subjects had been previously diagnosed with arterial hypertension and diabetes mellitus in 32.4% and 11.4% respectively. Exclusion criteria included clinical disorders that might affect the features needed for diagnosing MS (pregnancy, hypothyroidism and thyrotoxicosis) and/or death; nevertheless, none of the evaluated subjects had any of those criteria.</p>
      <p>In order to diagnose MS, we used the criteria of the United States' National Cholesterol Education Program (NCEP), as published in their 3<sup>rd</sup> guideline<sup>13</sup>. According to the NCEP, MS is diagnosed if the patient has one or more of the following features: abdominal obesity (as characterized by an abdominal circumference &gt; 102 cm for male subjects and &gt; 88 cm for females), high triglyceride serum levels (<underline>&gt;</underline> 150 mg/dl), low HDL-cholesterol levels (&lt; 40 mg/dl for males and &lt; 50 mg/dl for females), abnormal fasting glucose (<underline>&gt;</underline> 110 mg/dl) or use of oral hypoglicemiants and arterial blood pressure <underline>&gt;</underline> 130 x 85 mmHg or use of anti-hypertensive medications. </p>
      <p>During the first stage of the study a check-list with demographic and clinical-anthropometric data, including those criteria needed for the diagnosis of MS, was completed for each patient by reviewing their hospital files prior to the surgical intervention (bariatric surgery). The second phase was performed after surgery, when the patients were seen in an outpatient setting in order to reevaluate those parameters needed for the diagnosis of MS. All the laboratory tests used in this study were performed at the Central Clinical Analysis Laboratory of our UH. Prevalence of MS at the time of reevaluation was compared to that of the pre-surgical phase. </p>
      <p>The Epi Info 2007 program was used for statistical analysis. Qualitative variables were studied by analysis of relative frequency (%) and continuous variables were expressed as mean values and standard deviation. The chi-square test was used for analysis of significance when comparing proportions and the Wilcoxon's test for comparison of mean values. A significance cut-off value of 5% (p&lt;0.05) was adopted.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>During the basal period the mean Body Mass Index (BMI) was 44.9&#177;6.2 Kg/m<sup>2</sup>, ranging from 35.6 to 64.9 Kg/m<sup>2</sup>, and MS was diagnosed in 27 subjects (77.1%). At the time of re-evaluation 34.4&#177;15 months after surgery a decrease in BMI to 28.3&#177;5.0 Kg/m<sup>2</sup> (p=0.466) (range 17.9 to 39.9 Kg/m<sup>2</sup>) could be observed and MS was diagnosed in just two patients (5.7%) (p&lt;0.001) (<xref ref-type="table" rid="tab01-body3">table 1</xref>). Therefore, a mean reduction of 36.7% in BMI and a reduction of 92.6% of the prevalence of MS occurred as a result of BS.</p>
      <table-wrap id="tab01-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gt01-en.jpg"/></table-wrap>
      <p>Of all the diagnostic criteria of MS, according to the NCEP, during baseline the more prevalent were abdominal circumference, which was observed in all subjects, and low levels of HDL-cholesterol, found in 27 subjects (77.1%) (<xref ref-type="fig" rid="fig01-body3">Figure 1</xref>). In the follow-up evaluation there was an expressive reduction of all the NCEP criteria (<xref ref-type="fig" rid="fig01-body3">Figure 1</xref>) There was a marked reduction in the prevalence of abdominal circumference, glycemia, arterial blood pressure, HDL-cholesterol levels and triglycerides levels of 45.8%, 83%, 87.5%, 57.13% and 94%, respectively (<xref ref-type="fig" rid="fig02-body3">Figure 2</xref>). Abdominal circumference and low serum levels of HDL-cholesterol remained the more prevalent criteria, as they were identified in 54.3% and 34.3% of patients at follow-up. </p>
      <fig id="fig01-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gf01-en.jpg"/></fig>
      <fig id="fig02-body3">
        <graphic xlink:href="1678-4170-abc-92-06-0452-00007-gf02-en.jpg"/></fig>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>In spite of the fact that study population was comprised of relatively young patients, MS proved to be highly prevalent, leading to an early increased cardiovascular risk in these subjects. Considering the difficulties usually found in traditional measures for obtaining weight loss, bariatric surgery is currently a highly efficient method for obtaining substantial and sustained weight-loss in morbidly obese patients<sup>8</sup>. </p>
      <p>There are evidences that even smaller amount of weight loss, as small as 5% and 10% of original weight, result in clinically significant benefits, such as reduction of arterial blood pressure levels and fasting glucose levels<sup>14,15</sup>. Roux's Y gastrojejunal <italic>by-pass</italic> lead to sustained significant weight-loss that can be as substantial as 35% to 40% of initial weight<sup>16</sup>. A sensible supposition is that this more intense weight-loss may lead to even higher clinical benefits. Actively searching for MS, widely known to be associated with an increased risk of cardiovascular events<sup>3</sup>, was one of the end-points adopted in this study as a simple and objective measure in order toe valuate the benefits of bariatric surgery. </p>
      <p>The favorable effects of either Roux's Y gastrojejunal <italic>by-pass</italic> or adjustable gastric banding on the regression of MS had been reported in other samples with a follow-up as long as 12 months<sup>10-12,17</sup>. As ethnical features might affect the prevalence of MS, it was unknown whether these results could be extrapolated to our population. In addition, it was unclear if this benefit would be sustained over a more prolonged period of time. </p>
      <p>Similar to other results previously published, in this study bariatric surgery led to significant mid-term weight loss (mean 36.7% reduction). As hypothesized, the weight loss resulted in a significant reduction of the prevalence of MS (92.6%) in the study population in the follow-up evaluation mean period of three years following the surgical procedure. An important reduction of all the five diagnostic criteria of MS, according ton the NCEP, was also observed, and we highlight the marked reduction of fasting glucose levels, arterial blood pressure and triglyceride levels. Conversely, the remaining criteria; abdominal circumference and HDL- cholesterol, remained the most prevalent criteria in the late follow-up reevaluation. </p>
      <p>The benefits obtained after bariatric surgery might be due not only to the marked weight loss, but also to a change in the nutritional/alimentary profile, as a result of alimentary reeducation, as well as a more active life-style<sup>18,19</sup>. Several studies have shown that obesity, especially abdominal adiposity, had a defining role in the genesis of insulin-resistance, a physiopathological substrate for all the metabolic changes of MS<sup>20-22</sup>. Whichever the determining factors and mechanisms involved might be, the marked improvement of the metabolic profile observed in these patients strongly suggests that an important reduction of insulin-resistance, or even its reversal, may occur<sup>23</sup>.</p>
      <p>In addition, some authors have observed a significant improvement and even reversal/cure of diabetes mellitus type 2 quite early after bariatric surgery, even before significant weight-loss becomes evident, thus leading to the supposition that other alternative mechanisms might be responsible for this particular finding<sup>24-26</sup>.</p>
      <p>Recently incretines, peptides produced in the intestine, have been recognized as having a major role in the physiopathology of diabetes mellitus type 2. These substances, whose main representatives are GIP (gastric inhibitory peptide), which is secreted by K-cells in the proximal segment of the small-intestine, and GLP-1 (glucagon-like peptide-1), secreted by L-cells of the distal segment of the small intestine, have their secretion induced by direct contact of the alimentary bolus on the intestine. Once released, they act on the pancreas, stimulating the secretion of insulin. Other anti-diabetogenenic effects have been attributed to GLP-1, such as a slowing of gastric emptying, appetite reduction, glucagon inhibition and an improvement in the sensibility to insulin. However, type 2 diabetic patients have a reduced secretion of these substances following the alimentary stimulus. Thus, it has been hypothesized that Roux's Y gastrojejunal <italic>by-pass</italic>, by anatomically approaching the stomach and the ileum, leading to an earlier contact of the alimentary bolus with the distal intestine, would lead to an increase in the production of incretines. This, in turn, would explain the improvement or even reversal of diabetes mellitus type 2 by an additional mechanism other than weight loss. In fact, small preliminary studies have shown an early increase in the production of incretines following bariatric surgery, which may be confirmed in larger future studies<sup>24-28</sup>.</p>
      <p>Therefore, routine evaluation of patients who are candidates for bariatric surgery should include an active search for MS, due to its high prevalence, as shown in our study. Also, as a rather easy to perform evaluation, it should also be part of mid-term and long-term follow-up protocols, as an important parameter of the benefits of bariatric surgery in these individuals. Further studies should be able to demonstrate whether the favorable impact of bariatric surgery on MS is an effective tool in the reduction of long-term cardiovascular events. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
